US4666704A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release delivery system for macromolecules
Assignee: International Minerals and Chemical Corp
•
Filing: 1985-05-24
•
Granted: 1987-05-19
•
Expires: 2005-05-24
Abstract
Abstract A controlled release implant composition which includes a core comprising a macromolecular drug and a water insoluble polymer and a homogeneous outer polymeric membrane formed by coating said core with an organic solution of a water insoluble polymer and a water soluble pore-forming agent.
Inventors
- 👤 Mohamad D. Shalati
- 👤 Kallidaikurichi N. Sivaramakrishnan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 07:52
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/20; A61K9/2004; A61K9/2022; A61K9/2031; A61K9/204; A61K9/0012; A61K9/0019; A61K9/0024; A61K9/28; A61K9/2806; A61K9/2833; A61K9/2853; Y; Y10; Y10S; Y10S424/00; Y10S424/07
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
74 words
An implant composition which provides controlled release of a macromolecular drug at a substantially constant rate, said composition comprising a core of the macromolecular drug and a water insoluble polymer; and a homogeneous pore-forming outer polymeric membrane having a uniform distribution of pore-forming agents, said membrane formed by coating said core with a homogeneous solution of (a) an organic solvent, (b) a water insoluble high molecular weight polymer and (c) water soluble pore-forming agent.
Claim 2
Dependent Claim
74 words
An implant composition which provides controlled release of a macromolecular drug at a substantially constant rate, said composition comprising a core of the macromolecular drug and a water insoluble polymer; and a homogeneous pore-forming outer polymeric membrane having a uniform distribution of pore-forming agents, said membrane formed by coating said core with a homogeneous solution of (a) an organic solvent, (b) a water insoluble high molecular weight polymer and (c) water soluble pore-forming agent.
Claim 3
Dependent Claim
20 words
The composition of claim 1 wherein said macromolecular drug is a native or recombinant bioactive protein or an analog thereof.
Claim 4
Dependent Claim
18 words
The composition of claim 2 wherein said protein is native porcine growth hormone or a recombinant analog thereof.
Claim 5
Dependent Claim
18 words
The composition of claim 1 wherein said macromolecular drug has a molecular weight of at least about 2000.
Claim 6
Dependent Claim
21 words
The composition of claim 1 wherein said core polymer is selected from the group consisting of polylactic acid, ethylcellulose, and polycaprolactone.
Claim 7
Dependent Claim
23 words
The composition of claim 1 wherein said water soluble pore-forming agent is selected from the group consisting of dimethyl tartrate and diethyl tartrate.
Claim 8
Dependent Claim
29 words
The composition of claim 1 wherein said water insoluble, high molecular weight polymer in said polymeric membrane is selected from the group consisting of polylactic acid, ethylcellulose and polycaprolactone.
Claim 9
Independent Claim
85 words
A method of preparing an implant composition which provides controlled release of a macromolecular drug at a substantially constant rate which comprises: (a) forming a mixture of said macromolecular drug and a water insoluble polymer into a pellet; (b) coating said pellet with a homogeneous solution of (i) an organic solvent, (ii) a water insoluble high molecular weight polymer and (iii) a water soluble pore-forming agent; and (c) evaporating said organic solvent thereby forming an outer polymeric membrane having a uniform distribution of pore-forming agents.
Claim 10
Independent Claim
85 words
A method of preparing an implant composition which provides controlled release of a macromolecular drug at a substantially constant rate which comprises: (a) forming a mixture of said macromolecular drug and a water insoluble polymer into a pellet; (b) coating said pellet with a homogeneous solution of (i) an organic solvent, (ii) a water insoluble high molecular weight polymer and (iii) a water soluble pore-forming agent; and (c) evaporating said organic solvent thereby forming an outer polymeric membrane having a uniform distribution of pore-forming agents.
Claim 11
Dependent Claim
20 words
The method of claim 8 wherein said macromolecular drug is a native or recombinant bioactive protein or an analog thereof.
Claim 12
Dependent Claim
18 words
The method of claim 9 wherein said protein is native porcine growth hormone or a recombinant analog thereof.
Claim 13
Dependent Claim
18 words
The method of claim 8 wherein said macromolecular drug has a molecular weight of at least about 2000.
Claim 14
Dependent Claim
21 words
The method of claim 8 wherein said core polymer is selected from the group consisting of polylactic acid, ethylcellulose, and polycaprolactone.
Claim 15
Dependent Claim
23 words
The method of claim 8 wherein said water soluble pore-forming agent is selected from the group consisting of dimethyl tartrate and diethyl tartrate.
Claim 16
Dependent Claim
29 words
The method of claim 8 wherein said water insoluble, high molecular weight polymer in said polymeric membrane is selected from the group consisting of polylactic acid, ethylcellulose and polycaprolactone.
Claim 17
Dependent Claim
23 words
A method of treating an animal with the controlled release composition of claim 1 wherein said composition is subcutaneously implanted in said animal.
Claim 18
Dependent Claim
23 words
A method of treating an animal with the controlled release composition of claim 2 wherein said composition is subcutaneously implanted in said animal.
Claim 19
Dependent Claim
23 words
A method of treating an animal with the controlled release composition of claim 3 wherein said composition is subcutaneously implanted in said animal.
Claim 20
Dependent Claim
23 words
A method of treating an animal with the controlled release composition of claim 4 wherein said composition is subcutaneously implanted in said animal.
Claim 21
Dependent Claim
23 words
A method of treating an animal with the controlled release composition of claim 6 wherein said composition is subcutaneously implanted in said animal.
Claim 22
Dependent Claim
23 words
A method of treating an animal with the controlled release composition of claim 7 wherein said composition is subcutaneously implanted in said animal.
References Cited (Backward Citations)
US2987445A
Cited
US3538214A
Cited
US3773919A
Cited
US3558768A
Cited
AT305498B
Cited
US3835221A
Cited
GB1417527A
Cited
US4351337A
Cited
US4391797A
Cited
US4127127A
Cited
CH637832A5
Cited
US4148871A
Cited
GB2020181A
Cited
GB2025227A
Cited
US4459279A
Cited
EP0013131A2
Cited
EP0052510B1
Cited
US4377568A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-18 | 1990-11-17 | 1991-05-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-18 | 1994-11-17 | 1995-05-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-18 | 1998-11-17 | 1999-05-19 | $7700.00 | Window Closed / Lapsed |